The experimental group will receive intralesional injections of platelet-rich plasma, evaluating its ability to relieve pain and provide sustained improvement through biological modulation of the joint and tendon environment. In contrast, the control group will be treated with a combination of betamethasone and ropivacaine, representing the current standard of care for short-term inflammatory pain management. The comparison between these two options will determine whether platelet-rich plasma offers advantages in terms of clinical efficacy and duration of benefits. The results obtained could contribute significantly to the development of more effective protocols and more precise management guidelines for patients with chronic omalgia, thus addressing existing controversies and improving clinical practice.
Patients between 35 and 75 years of age, both inclusive.
Presence of pain in the affected shoulder for 3 or more months.
Body Mass Index (BMI) values between 20 and 27 kg/m2, including both values.
Confirmed diagnosis of chronic shoulder pain associated with rotator cuff tendinopathy, following an unfavorable response to standard treatment with analgesics and nonsteroidal anti-inflammatory drugs for 4-6 weeks.
Confirmed diagnosis of complete rotator cuff tear.
Patients with systemic autoimmune rheumatic disease (connective tissue diseases and systemic necrotizing vasculitis).
Patients with diabetes mellitus.
Patients with hematological disorders (thrombopathy, thrombocytopenia, anemia with Hb<9 g/dl).